無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のインフルエンザワクチン市場:産業分析と見通し

Global Influenza Vaccine Market: Industry Analysis & Outlook 2017-2021

発行 Koncept Analytics 商品コード 431655
出版日 ページ情報 英文 79 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.42円で換算しております。
Back to Top
世界のインフルエンザワクチン市場:産業分析と見通し Global Influenza Vaccine Market: Industry Analysis & Outlook 2017-2021
出版日: 2017年01月27日 ページ情報: 英文 79 Pages
概要

当レポートでは、世界のインフルエンザワクチン市場について調査分析し、セグメント別の分析、地域別の分析、市場力学、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

第1章 市場概要

  • インフルエンザ
  • インフルエンザワクチン

第2章 世界のインフルエンザワクチン市場の分析

  • 世界のインフルエンザワクチン市場:金額別
  • 世界のインフルエンザワクチン市場の予測:金額別
  • 世界のインフルエンザワクチン生産能力:適応別
  • 世界のインフルエンザワクチン生産能力
  • 世界のインフルエンザワクチン市場:地域別

第3章 地域別のインフルエンザワクチン市場の分析

  • 米国
  • 日本
  • ドイツ

第4章 市場力学

  • 主要動向と発展
  • 成長促進要因
  • 課題と問題

第5章 競合情勢

  • 世界のインフルエンザワクチン市場
  • 米国のインフルエンザワクチン市場

第6章 企業プロファイル

  • 事業概要、財務概要、事業戦略
    • Novartis AG
    • Sanofi S.A
    • GlaxoSmithKline Plc.
    • AstraZeneca
目次

Influenza, also known as flu, is a contagious disease which spreads from person to person very rapidly. When an infected person sneezes or coughs the virus spreads to those close by, affecting immuno-compromised patients the most. The influenza virus is broadly classified as influenza A, influenza B, and influenza C. The influenza vaccine come in both inactive and weakened viral forms.

The global influenza vaccine market is relatively untouched and has huge potential to treat any major outbreak. The influenza vaccine market in the US is the largest market globally because of its strong dynamics and a great scope of innovation in the region. The growth factors of the market include increase in incidence of H1N1 outbreaks, rising spending on public healthcare programs, growth of the market in emerging economies, escalating ageing population and increase in spending on medicines and healthcare expenditure.

The global influenza vaccine market is trending with development of new drugs, use of new technologies, rise in FDA approvals, and increase in efficiency rate of influenza vaccines, booming public private partnership and growing awareness. However, the market growth will be hindered by complex development and production process, unclear process for introduction of new vaccines and high R&D costs.

The report offers an in-depth analysis of the global influenza vaccine market along with regional insights. The top notch players in the market exhibit a very close competition. The report profiles Sanofi S.A, Novartis AG, AstraZeneca PLC and GlaxoSmithKline Plc.

Table of Contents

1. Market Overview

  • 1.1. Influenza
    • 1.1.1. Types of Influenza
    • 1.1.2. Symptoms
  • 1.2. Influenza Vaccine
    • 1.2.1. Types
    • 1.2.2. Supply Chain of Influenza Vaccine
    • 1.2.3. Side Effects

2. Global Influenza Vaccine Market Analysis

  • 2.1. Global Influenza Vaccine Market by Value
  • 2.2. Global Influenza Vaccine Market Forecast by Value
  • 2.3. Global Influenza Vaccine Production Capacity by Indication
  • 2.4. Global Influenza Vaccine Production Capacity
    • 2.4.1. Global Pandemic Influenza Vaccine Production Capacity
    • 2.4.2. Global Pandemic Influenza Vaccine Production Capacity Forecast
    • 2.4.3. Global Seasonal Influenza Vaccine Production Capacity
    • 2.4.4. Global Seasonal Influenza Vaccine Production Capacity Forecast
  • 2.5. Global Influenza Vaccine Market by Region

3. Regional Influenza Vaccine Market Analysis

  • 3.1. The US
    • 3.1.1. The US Influenza Vaccine Market by Value
    • 3.1.2. The US Influenza Vaccine Market Forecast by Value
    • 3.1.3. The US Influenza Vaccine Production Volume
    • 3.1.4. The US Influenza Vaccine Production Volume Forecast
    • 3.1.5. The US Influenza Vaccine Market Volume by Type
  • 3.2. Japan
    • 3.2.1. Japan's Influenza Vaccine Market by Value
    • 3.2.2. Japan's Influenza Vaccine Market Forecast by Value
  • 3.3. Germany
    • 3.3.1. Germany's Influenza Vaccine Market by Value
    • 3.3.2. Germany's Influenza Vaccine Market Forecast by Value

4. Market Dynamics

  • 4.1. Key Trends & Developments
    • 4.1.1. Increase in Development of New Drugs
    • 4.1.2. Use of New Technology
    • 4.1.3. Rise in FDA Approvals
    • 4.1.4. Influenza Vaccine Effectiveness
    • 4.1.5. Booming Public-Private Corporation
    • 4.1.6. Public Awareness on Rise
  • 4.2. Growth Drivers
    • 4.2.1. Development of H1N1/H5N1 Vaccines
    • 4.2.2. Rise of Retail Clinics
    • 4.2.3. Rising Spending on Public Health Programs
    • 4.2.4. Growing Influenza Vaccine Market in Emerging Economies
    • 4.2.5. Increased Spending on Medicines
    • 4.2.6. Increasing Global Healthcare Expenditure
    • 4.2.7. Escalating Ageing Population
  • 4.3. Challenges & Issues
    • 4.3.1. Complex Development and Production Process
    • 4.3.2. Unclear Process in Introducing New Vaccines
    • 4.3.3. High R&D Costs

5. Competitive Landscape

  • 5.1. Global Influenza Vaccine Market
    • 5.1.1. Market Share Comparison
    • 5.1.2. Competition by Drugs & Indication
    • 5.1.3. Revenue Comparison
    • 5.1.4. Market Cap Comparison
  • 5.2. The US Influenza Vaccine Market
    • 5.2.1. Production Volume Share

6. Company Profiles

  • 6.1. Novartis AG
    • 6.1.1. Business Overview
    • 6.1.2. Financial Overview
    • 6.1.3. Business Strategies
  • 6.2. Sanofi S.A
    • 6.2.1. Business Overview
    • 6.2.2. Financial Overview
    • 6.2.3. Business Strategies
  • 6.3. GlaxoSmithKline Plc.
    • 6.3.1. Business Overview
    • 6.3.2. Financial Overview
    • 6.3.3. Business Strategies
  • 6.4. AstraZeneca
    • 6.4.1. Business Overview
    • 6.4.2. Financial Overview
    • 6.4.3. Business Strategies

List of Charts

  • Types of Influenza
  • Symptoms of Influenza
  • Supply Chain of Influenza Vaccine
  • Global Influenza Vaccine Market by Value (2012-2016)
  • Global Influenza Vaccine Market Forecast by Value (2017-2021)
  • Global Influenza Vaccine Production Capacity by Indication (2016)
  • Global Pandemic Influenza Vaccine Production Capacity (2012-2016)
  • Global Pandemic Influenza Vaccine Production Capacity Forecast (2017-2021)
  • Global Seasonal Influenza Vaccine Production Capacity (2012-2016)
  • Global Seasonal Influenza Vaccine Production Capacity Forecast (2017-2021)
  • Global Influenza Vaccine Market by Region (2016)
  • The US Influenza Vaccine Market by Value (2012-2016)
  • The US Influenza Vaccine Market Forecast by Value (2017-2021)
  • The US Influenza Vaccine Production Volume (2012-2016)
  • The US Influenza Vaccine Production Volume Forecast (2017-2021)
  • The US Influenza Vaccine Market Volume by Type (2016)
  • Japan's Influenza Vaccine Market by Value (2012-2016)
  • Japan's Influenza Vaccine Market Forecast by Value (2017-2021)
  • Germany's Influenza Vaccine Market by Value (2012-2016)
  • Germany's Influenza Vaccine Market Forecast by Value (2017-2021)
  • Vaccine Effectiveness for Influenza Seasons (2005-2016)
  • Global Spending on Medicines (2010-2020E)
  • Total Spending on Medicines in the US (2012-2016)
  • Global Healthcare Expenditure (2012-2016)
  • Global Ageing Population of 60 Years or Older (2000-2030E)
  • Global Influenza Vaccine Market Share (2016)
  • Revenue Comparison by Key Players (2016)
  • Market Cap Comparison by Key Players (2016)
  • The US Influenza Vaccine Production Volume Share (2016)
  • Novartis Revenue Share by Segments (2015)
  • Novartis AG's Revenue and Net Income (2012-2015)
  • Sanofi S.A Net Sales Share by Business Segments (2015)
  • Sanofi S.A Net Sales and Net Income (2012-2015)
  • GlaxoSmithKline Plc. Net Sales Share by Segments (2015)
  • GlaxoSmithKline Plc. Net Sales and Operating Profit (2012-2015)
  • AstraZeneca Revenue by Segment (2015)
  • AstraZeneca's Revenue (2012-2015)

List of Tables

  • Difference between Influenza Types A, B and C Viruses
  • Influenza Vaccine Side Effects
  • Flu Vaccines Lots Released by the FDA (2016/2017)
  • H1N1/H5N1 Vaccine in Development (2015-2016)
  • Number of Retail Clinics in the US (2015)
  • Global Influenza Vaccine Market Competition by Drugs & Indication (2016)
  • Sanofi S.A Key Product Enhancement Strategies (2015)
  • GlaxoSmithKline Plc. Core R&D Expenditure Allocation (2015)
  • GSK Product Development Pipeline in Pharmaceutical and Vaccine Segment (2015)
  • AstraZeneca's Approvals and Upcoming Drugs (2015)
Back to Top